Listings

QTREX Quantum (QTEX) regains Nasdaq minimum bid price compliance

QTEX

QTREX Quantum Ltd. said on October 19, 2026 that Nasdaq confirmed on October 16 that it regained compliance with the $1.00 minimum bid price, after 10 business days above $1.00.

Investor Chat

Scorecard

QTEX
Investor Impact: 3/10, LimitedHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
LimitedHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-08
Mixed record
Investment Attractiveness: 4.3/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed

By the aibio.space news desk

The Great Room in an FDA building
The Great Room in an FDA building. Photo: The U.S. Food and Drug Administration, Public domain, via Wikimedia Commons. The picture shows the field, not the companies named.

QTREX Quantum Ltd. (Nasdaq: QTEX) said on October 19, 2026 that Nasdaq had confirmed in writing on October 16, 2026 that the company regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq found that the closing bid was at or above $1.00 for 10 consecutive business days, from October 2, 2026 to October 15, 2026. The company reported the confirmation in a Form 6-K dated October 19, 2026.

Why is this important: The matter is closed, and the shares remain listed on the Nasdaq Capital Market under QTEX. The notice that opened it came on October 5, 2026, after 30 consecutive business days below $1.00 from August 20 through October 1, 2026. The recovery ran for exactly the 10 business days Nasdaq requires, so the margin was narrow. The August offering price of $0.90 still sits below $1.00.

Dagi Ben-Noon, the chief executive officer, signed the October 19, 2026 Form 6-K. In our view, the company cleared the bid test on a short run of days, not on a sustained recovery. The notice says the bid was below $1.00 on every one of the 30 business days from August 20, 2026, the day the company agreed to a registered direct offering at $0.90 a share. The 6-K does not say how the bid will trade from here.

What the confirmation closes

Nasdaq Listing Rule 5550(a)(2) requires a $1.00 minimum closing bid for continued listing on the Nasdaq Capital Market. The company's 6-K dated October 9, 2026 reported a notice received on October 5, 2026, which gave it 180 calendar days, until April 3, 2027, to regain compliance. That notice had no immediate effect on the listing or trading of the ordinary shares. The confirmation closed the matter before that deadline.

The measurement period began on August 20, 2026, the day the company agreed to sell 11,111,111 ordinary shares at $0.90 each. The prospectus supplement for that sale lists a last reported sale price of $1.12 on August 19, 2026, and estimates net proceeds of about $9.1 million after offering expenses. The placement agent, A.G.P./Alliance Global Partners, receives a fee of 7.0% of the gross proceeds.

The company's cash and technology before the confirmation

QTREX Quantum, formerly Inspira Technologies Oxy B.H.N. Ltd, describes itself as focused on Additively Manufactured Electronics, or AME, for quantum computing infrastructure. Its first-half 2026 results, released on September 24, 2026 in a Form 6-K, show cash, cash equivalents and deposits of $10.7 million on June 30, 2026, compared with $3.2 million on December 31, 2025. Net cash used in operating activities was $3.9 million for the six months, compared with $5.1 million a year earlier. Revenue for the period was $1.55 million, all generated by the AME and Quantum segment. The company completed its acquisition of the AME platform on April 6, 2026 for $2.0 million in cash at closing.

The same results release says the INSU300, described as the first native RF dielectric for superconducting quantum computing, launched on September 23, 2026, with a dedicated AME system. The company's technology targets the cryogenic wiring that carries signals to qubits inside a dilution refrigerator. The filings describe no clinical trial for the company's products.

What is still open

The September 24, 2026 results said the company expected to announce additional commercial agreements in the fourth quarter of 2026, and to give a 2027 financial outlook in the same quarter. The October 19, 2026 6-K does not mention either item. It furnishes the company's press release as Exhibit 99.1, titled QTREX Regains Compliance with Nasdaq Minimum Bid Price Requirement. The prospectus warns that the issuance of securities could result in further dilution to shareholders.

The 6-K does not say whether the company expects the bid to stay above $1.00. Holders will see that answer only in the company's later filings and in the closing bid price itself.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.